297 related articles for article (PubMed ID: 27748439)
1. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
Maity SN; Titus MA; Gyftaki R; Wu G; Lu JF; Ramachandran S; Li-Ning-Tapia EM; Logothetis CJ; Araujo JC; Efstathiou E
Sci Rep; 2016 Oct; 6():35354. PubMed ID: 27748439
[TBL] [Abstract][Full Text] [Related]
2. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer.
Toren PJ; Kim S; Pham S; Mangalji A; Adomat H; Guns ES; Zoubeidi A; Moore W; Gleave ME
Mol Cancer Ther; 2015 Jan; 14(1):59-69. PubMed ID: 25351916
[TBL] [Abstract][Full Text] [Related]
3. A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
Moll JM; Kumagai J; van Royen ME; Teubel WJ; van Soest RJ; French PJ; Homma Y; Jenster G; de Wit R; van Weerden WM
Prostate; 2019 Jun; 79(9):937-948. PubMed ID: 31017696
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
[TBL] [Abstract][Full Text] [Related]
5. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
[TBL] [Abstract][Full Text] [Related]
6. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
[TBL] [Abstract][Full Text] [Related]
7. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Bird IM; Abbott DH
J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP
Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
10. Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis.
Xiao L; Wang Y; Xu K; Hu H; Xu Z; Wu D; Wang Z; You W; Ng CF; Yu S; Chan FL
Cancer Res; 2018 May; 78(9):2205-2218. PubMed ID: 29438990
[TBL] [Abstract][Full Text] [Related]
11. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer.
Yang Y; Bai Y; He Y; Zhao Y; Chen J; Ma L; Pan Y; Hinten M; Zhang J; Karnes RJ; Kohli M; Westendorf JJ; Li B; Zhu R; Huang H; Xu W
Clin Cancer Res; 2018 Feb; 24(4):834-846. PubMed ID: 29167276
[No Abstract] [Full Text] [Related]
12. CYP17A1 inhibitors in castration-resistant prostate cancer.
Gomez L; Kovac JR; Lamb DJ
Steroids; 2015 Mar; 95():80-7. PubMed ID: 25560485
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
14. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
Mostaghel EA; Marck BT; Plymate SR; Vessella RL; Balk S; Matsumoto AM; Nelson PS; Montgomery RB
Clin Cancer Res; 2011 Sep; 17(18):5913-25. PubMed ID: 21807635
[TBL] [Abstract][Full Text] [Related]
15. Limited in vitro efficacy of CYP17A1 inhibition on human castration resistant prostate cancer.
Kosaka T; Miyajima A; Yasumizu Y; Miyazaki Y; Kikuchi E; Oya M
Steroids; 2014 Dec; 92():39-44. PubMed ID: 25150014
[TBL] [Abstract][Full Text] [Related]
16. Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.
Lim AC; Attard G
Curr Drug Targets; 2013 Apr; 14(4):408-19. PubMed ID: 23565754
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
Chen EJ; Sowalsky AG; Gao S; Cai C; Voznesensky O; Schaefer R; Loda M; True LD; Ye H; Troncoso P; Lis RL; Kantoff PW; Montgomery RB; Nelson PS; Bubley GJ; Balk SP; Taplin ME
Clin Cancer Res; 2015 Mar; 21(6):1273-80. PubMed ID: 25320358
[TBL] [Abstract][Full Text] [Related]
18. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.
Han D; Gao S; Valencia K; Owiredu J; Han W; de Waal E; Macoska JA; Cai C
Oncotarget; 2017 Jan; 8(4):6796-6808. PubMed ID: 28036278
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
Norris JD; Ellison SJ; Baker JG; Stagg DB; Wardell SE; Park S; Alley HM; Baldi RM; Yllanes A; Andreano KJ; Stice JP; Lawrence SA; Eisner JR; Price DK; Moore WR; Figg WD; McDonnell DP
J Clin Invest; 2017 Jun; 127(6):2326-2338. PubMed ID: 28463227
[TBL] [Abstract][Full Text] [Related]
20. [Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer].
Ripert T; Crouzet S; Ploussard G; De La Taille A; Robert G
Prog Urol; 2013 Oct; 23 Suppl 1():S16-22. PubMed ID: 24314735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]